BidAs iscfa worries about a few million in legal fees another bid for 1,000,000 shares at $.24 appears to have been put in place last week. That after the bid for ~1.75 million shares. With the closure of the merger, expected this quarter, are we about to see institutions get involved through Bloom Burton? An analyst report? H.C. Wainwright had a C$100 million market cap target for AEZS before the merger announcement. AEZS's diagnostic trial is now fully enrolled and top-line results are expected in Q3. Does the avenanthramide pill now have a path forward given results to date with no adverse events? A comprehensive package for the fibrosis drug is also submitted for publishing in a scientific journal. PGX may be about to clear the 5X scale-up which was to provide materials for potential partners to evaluate as the 10X scale-up continues on plan with industry leader Natex.